Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTNT.L Regulatory News (TNT)

  • There is currently no data for TNT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (DD) - Offeree Concert Party - Tintra plc

6 Oct 2023 09:35

RNS Number : 9833O
Tintra PLC
06 October 2023
 

FORM 8 (DD)

 

PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS)

Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

The Tintra Foundation

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

The Tintra Foundation is an independently managed foundation based in Switzerland which receives support from Tintra PLC as part of its ESG strategy.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Tintra PLC

(d) Status of person making the disclosure:

e.g. offeror, offeree, person acting in concert with the offeror/offeree (specify name of offeror/offeree)

RR Mathews, director of Oyster Trust SARL, Trustee of the Tintra Foundation

(e) Date dealing undertaken:

5 October 2023

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

 

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing

 

Class of relevant security:

 

1p Ordinary Shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

160,000

0.90

 

 

(2) Cash-settled derivatives:

 

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

 

TOTAL:

160,000

0.90

 

 

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

(i) Party to an offer or person acting in concert (except for a principal trader in the same group as a connected adviser)

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ordinary

Sale

 

5,000

92.5p

Ordinary

Sale

 

25,000

85.0p

 

(ii) Principal trader where the sole reason for the connection is that the principal trader is in the same group as a connected adviser

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

 

 

 

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer or person acting in concert making the disclosure and any other person:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer or person acting in concert making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

None

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

6 October 2023

Contact name:

RR Matthews

Telephone number:

07781 102525

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DCCUPGPWUUPWURQ
Date   Source Headline
2nd Jun 20237:00 amRNSTotal Voting Rights & Licence Update
25th May 20232:17 pmRNSUpdate on UK Licence Application
23rd May 20239:38 amRNSReplacement - Director/PDMR Shareholding
16th May 20232:00 pmRNSNew Patent Applications
5th May 202312:32 pmRNSUpdate in relation to the Placement Facility
4th May 20237:00 amRNSConversion of Loan Stock and Total Voting Rights
6th Apr 20231:08 pmRNSRepayment Under Placement Facility
31st Mar 20235:00 pmRNSTotal Voting Rights
31st Mar 202311:55 amRNSParticipation in the Call to Advance Democracy
30th Mar 20233:00 pmRNSDirector/PDMR Shareholding
17th Mar 20232:15 pmRNSDirector/PDMR Shareholding
13th Mar 20233:07 pmRNSNotification of US Patent to Protect Web3 IP
10th Mar 202310:30 amRNSStrategic investment under current funding round
9th Mar 20237:00 amRNSKey Management Appointment & Directorate Change
8th Mar 20239:30 amRNSTintra to establish new hub in Rwanda
3rd Feb 20237:00 amRNSKey Management Appointment
2nd Feb 202311:00 amRNSUpdate on US Patent Applications
30th Jan 20237:45 amRNSIssue of Ordinary Shares Under Funding Round
25th Jan 20237:00 amRNSAppointment of Chief Operating Officer
16th Jan 20234:40 pmRNSSecond Price Monitoring Extn
16th Jan 20234:35 pmRNSPrice Monitoring Extension
3rd Jan 20237:00 amRNSTotal Voting Rights
21st Dec 20221:00 pmRNSHolding(s) in Company
16th Dec 20227:30 amRNSUS$10,000,000 Placement Facility
16th Dec 20227:00 amRNSStrategic Investment Under Current Funding Round
30th Nov 20223:31 pmRNSUpdate on Funding Round
8th Nov 20229:00 amRNSIssue of Convertible Loan Notes & PCA Holding
8th Nov 20227:30 amRNSBusiness Update
27th Oct 20227:00 amRNSHalf-year Report to 31 July 2022
18th Oct 202212:00 pmRNSUpdate on PPS Asset Realisation Co Limited
4th Oct 202212:00 pmRNSTotal Voting Rights
27th Sep 20227:00 amRNSUpdate on PPS Asset Realisation Co Limited
22nd Sep 20227:00 amRNSAppointment of Chief Innovation Officer
21st Sep 20226:00 pmRNSExercise of Options & Conversion Rights
21st Sep 202211:05 amRNSResult of Adjourned AGM
14th Sep 202210:30 amRNSGranting of Middle East Licence
14th Sep 20227:00 amRNSContract with Temenos for Core Banking Software
24th Aug 202210:30 amRNSNotice of Reconvening of AGM & Supplementary Note
1st Aug 20227:00 amRNSFinal Results & Annual Report for Yr to 31 Jan 22
29th Jul 202210:36 amRNSResult of AGM
29th Jul 20227:00 amRNSAGM Statement
11th Jul 20222:00 pmRNSUS Patent Application Filings to Protect Web3 IP
7th Jul 20227:00 amRNSFiling of UK Patent Application & Notice of AGM
28th Jun 20227:00 amRNSAI in banking needs to be 'explainable'
27th Jun 20227:00 amRNSAppointment of Chief Science Officer
16th Jun 20227:00 amRNSPatent Application
15th Jun 20227:00 amRNSWestern banks prefer metaverse to emerging markets
8th Jun 20227:00 amRNSThe importance of financial inclusion
20th May 20227:00 amRNSBusiness Update
29th Apr 20225:30 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.